Welcome to our dedicated page for Lisata Therapeutics SEC filings (Ticker: LSTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lisata Therapeutics, Inc. (LSTA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lisata is a clinical-stage pharmaceutical company focused on certepetide, an investigational internalizing RGD cyclic peptide being developed for advanced solid tumors and other serious diseases. Its filings help investors understand how clinical progress, licensing agreements and intellectual property developments are reflected in formal reports.
Recent Form 8-K filings from Lisata have covered topics such as quarterly financial results, preliminary clinical data from the ASCEND trial in metastatic pancreatic ductal adenocarcinoma, corporate presentations used at investor and industry conferences, a new composition of matter patent for certepetide and a worldwide non-exclusive license agreement with Catalent, Inc. for use of certepetide as a SMARTag® antibody-drug conjugate payload. These current reports provide timely detail on material events, including business development milestones and updates to the company’s cash runway expectations.
Through this page, users can track Lisata’s ongoing 8-K disclosures and, as they are filed, review annual reports on Form 10-K, quarterly reports on Form 10-Q, and other materials that describe the company’s clinical programs, risk factors, intellectual property, and financial condition. Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as new trial data descriptions, changes in development strategy, or licensing and patent developments related to certepetide.
For those following LSTA, this filings archive offers a structured view of Lisata’s regulatory history, from clinical and business updates reported on Form 8-K to broader periodic reports that outline the company’s operations and oncology-focused development plans.
Lisata Therapeutics (Nasdaq:LSTA) filed an 8-K (Item 7.01 Regulation FD) announcing preliminary cohort B data from its Phase 2 ASCEND trial evaluating certepetide plus standard chemotherapy in metastatic pancreatic ductal adenocarcinoma. The company furnished a press release (Ex. 99.1) and investor slide deck (Ex. 99.2); the 8-K itself contains no numerical efficacy or safety results. Because the information is furnished, it is not deemed “filed” under the Exchange Act and carries no Section 18 liability. The disclosure is potentially material given certepetide’s status as the lead asset targeting a high-mortality cancer, yet the market impact depends on data contained only in the exhibits.